Möchten Sie immer auf dem neuesten Stand bleiben?

Consideration of up to $29.00 per share includes $27.50 per share in upfront cash and an additional $1.50 per share upon regulatory approval of DOPTELET® for chemotherapy-induced thrombocytopenia...

DURHAM, N.C., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019...

DURHAM, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President & Chief Executive Officer, will present company...

DURHAM, N.C., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019...

DOPTELET® (avatrombopag) approved by U.S. Food and Drug Administration (FDA) for treatment of chronic immune thrombocytopenia (ITP); commercial launch occurred mid-JulyDOPTELET approved by European...

DURHAM, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Tuesday, August 6, 2019 at 9:00 a.m. ET to discuss second quarter 2019...

DURHAM, N.C., July 19, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases...

Company Strengthens Thrombocytopenia Portfolio with ITP Approval and Expanded Partnership with Salix for Chronic Liver Disease (CLD) Indication Company to Host Conference Call at 9am EST DURHAM,...

-Approval Based on Positive Efficacy and Safety Data from Two Phase 3 Clinical Trials- -Company Intends to Partner for the European Commercialization of DOPTELET- DURHAM, N.C., June 25, 2019 ...

DURHAM, N.C., June 24, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced the Company will present four abstracts with data from studies of avatrombopag in patients...